Portage Biotech Inc

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Portage Biotech, Inc. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

- $29 million raised during quarter with broad institutional support

Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year

WESTPORT, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the first patient has been dosed in the Oxford-led IMP-MEL study, a Phase 1/2, open-label, dose-escalation and randomized expansion clinical trial assessing the safety, tolerability and efficacy of PORT-2, a liposome formulation of the invariant natural killer T-cell (iNKT) agonist IMM60 developed for the treatment of solid tumors.

Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)

-  Transformative year included multiple corporate, clinical, and financial milestones, positioning Portage to accelerate development of first-in-class immuno-oncology assets -  Additional clinical milestones and company progress anticipated throughout 2H 2021 and 2022

Portage Biotech Announces Results for Fiscal Year Ended March 31, 2021

Westport, Connecticut--(Newsfile Corp. - June 29, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the Company has been added to the Russell 2000 Index at the conclusion of the 2021 Russell Indexes annual reconstitution, effective after the U.S. market opened on June 28. "Inclusion in the Russell 2000 index marks another key milestone for Portage,...

Portage Biotech Added to Russell 2000(R) Index

Westport, Connecticut--(Newsfile Corp. - June 24, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that it has priced its previously announced underwritten public offering of 1,000,000 ordinary shares. The public offering price of each ordinary share is $23.00. In addition, Portage has granted the underwriters a 30-day option to purchase up to an additional...

Portage Biotech Inc. Announces Pricing of Public Offering of 1,000,000 Ordinary Shares

Westport, Connecticut--(Newsfile Corp. - June 23, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that it has commenced an underwritten public offering of its ordinary shares. In addition, Portage expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of the ordinary shares sold in connection...

Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares

- Data from the IT-01 trial demonstrate the safety of INT230-6 (PORT-1) as both a monotherapy and in combination with checkpoint inhibitors in solid tumors - Survival data looks favorable compared to similar historical populations, balanced for prognostic factorsWestport, Connecticut--(Newsfile Corp. - June 2, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage...

Portage Biotech Highlights Safety and Survival Data from Intensity Therapeutics' IT-01 Study of INT230-6 (PORT-1) at ASCO 2021 Annual Meeting

Common shares will be consolidated on the Nasdaq exchange where shareholders can continue trading under the symbol "PRTG"Westport, Connecticut--(Newsfile Corp. - April 16, 2021) -  Portage Biotech Inc., (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that it plans to voluntarily delist its common shares ("Shares") from the Canadian Securities Exchange (the "CSE"). Since Portage's Shares began trading on the NASDAQ Capital Market ("Nasdaq") in February 2021, the majority of active trading has shifted to Nasdaq....

Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange

- Novel platform allows co-targeting of iNKT cells and tumor antigens in a single product- Trial marks the first milestone in a comprehensive clinical development plan to evaluate iNKT agonists to improve outcomes in a variety of solid tumors Westport, Connecticut--(Newsfile Corp. - April 8, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or...

Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors

- The INVINCIBLE trial is a phase 2 study with a primary endpoint one month after starting treatment - Eight other phase 2 clinical data reads are expected from INT230-6 (PORT-1) over the next 24 monthsWestport, Connecticut--(Newsfile Corp. - March 25, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance,...

Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeutics

News for Portage Biotech Inc Stock (PRTG)